Purchase Order 75N94026P00115

<p>The National Institute on Alcohol Abuse and Alcoholism awarded a purchase order to Oxford Nanopore Technologies Inc. for $83,900.00 on July 10, 2026, for PromethION flow cell packs (DNA and RNA volumes) on a firm fixed price basis.</p> <p>Performance occurs in New York, New York. The order is not set-aside. Ultimate completion is scheduled for July 9, 2027.</p>

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $90.1K firm fixed-price purchase order to Oxford Nanopore Technologies Inc. for a PromethION 2 integrated sequencing unit and related support services. This severable purchase order (ONT-077966) was awarded on July 18, 2025, with an ultimate completion date of July 17, 2026, and will be performed in New York, NY. The award includes no set-aside designation and represents a direct procurement of advanced genomic sequencing...

The National Institute on Alcohol Abuse and Alcoholism (NIAAA), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), awarded a $17,380 purchase order to Oxford Nanopore Technologies Inc. for CAS9 sequencing kits. The firm fixed price order is for delivery of the requested products between July 24 and August 4, 2023. Oxford Nanopore Technologies Inc. will perform as the prime contractor, with all work taking place in New York, NY....

The Department of Health and Human Services National Institutes of Health National Institute on Alcohol Abuse and Alcoholism awarded a firm fixed price purchase order valued at thirty-two thousand two hundred eighty dollars to Oxford Nanopore Technologies Inc. for DNA sequencing kits and PromethION flow cell packs. The solicitation requested quotes for six ultra-long DNA sequencing kits and one pack of eight PromethION flow cells to support long read DNA and RNA sequencing on the awardee's...

The National Institute on Alcohol Abuse and Alcoholism awarded a purchase order to Human Metabolome Technologies America, Inc. for $17,000.00 on June 18, 2026, with final completion by June 17, 2027. The order is firm fixed price with no set-aside category. Performance occurs in Boston, Massachusetts. The National Institute on Alcohol Abuse and Alcoholism conducts studies to determine the contribution of genetics and metabolomics in the etiology of substance abuse disorders through the...

<p>The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a purchase order to Norgen Biotek Corp for $27,179.25 on July 24, 2026. The order covers exosomal RNA services including RNA purification from intact exosomes with quality control testing and small RNA sequencing library preparation. Work is performed in Bethesda, Maryland, with an ultimate completion date of July 23, 2027. The purchase order is firm fixed-price with no set-aside designation.</p>

<p>The National Institute on Alcohol Abuse and Alcoholism awarded a purchase order to Illumina, Inc. on July 8, 2026 for an Infinium Global Diversity Array-8 V1.0 kit (96 samples) with a total value of $24,031.45 on a firm fixed-price basis. Place of performance is Bethesda, Maryland. The order is not set-aside. Ultimate completion is July 7, 2027.</p>

<p>The National Institute on Alcohol Abuse and Alcoholism issued a delivery order to Illumina, Inc. on August 28, 2017, with a ceiling value of $9,819.42 for an Infinium OmniExpressExome 8 sequencing kit.</p> <p>Place of performance is Bethesda, MD. The order is firm fixed price with an ultimate completion date of September 2, 2020. No set-aside was used.</p>

<p>The National Institute on Alcohol Abuse and Alcoholism issued a $25,459.20 delivery order to Illumina, Inc. on August 7, 2019, for genetic sequencing equipment and related genomic analysis technologies.</p> <p>Place of performance is Bethesda, Maryland. The order has a firm fixed price and an ultimate completion date of September 2, 2020. No set-aside was used.</p>

The National Institute on Alcohol Abuse and Alcoholism awarded a purchase order to Revvity Health Sciences, Inc. (doing business as PerkinElmer Inc.) valued at $16,878.10 on June 16, 2026. No set-aside category was used. Performance occurs in North Bethesda, Maryland. The order procures support for medicinal chemistry work focused on developing new molecular entities to assess translational potential for improving treatment of metabolic diseases. The order is firm fixed price with an ultimate...